Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Pedmark study for prevention of cisplatin-induced hearing loss in children and AYA patients
jRCT2061220018Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium thiosulfate in cisplatin-induced ototoxicity, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Ratio of hearing impairment using the ASHA assessment method at the end of protocol treatment. Started Sep 2022; status: completed.
02
Drugs
sodium thiosulfate
03
Conditions
cisplatin-induced ototoxicity
Beyond the preview
Go deeper on jRCT2061220018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220018.